VolitionRx Limited Form 8-K Summary
Business Context and Reporting Period
VolitionRx Limited filed a Current Report on Form 8-K dated September 25, 2026, reporting events occurring on September 18 and September 23, 2026. The company’s common stock trades on the NYSE American under the symbol VNRX.
Material Transaction
- Under a securities purchase agreement originally dated May 15, 2025 and amended and restated January 7, 2026, the company issued Lind Global Asset Management XII LLC a senior secured convertible promissory note with an original principal amount of $2.4 million.
- On September 18, 2026, VolitionRx issued 698,113 common shares to Lind to satisfy a $185,000 conversion obligation.
- On September 23, 2026, VolitionRx issued 1,459,227 common shares to Lind to satisfy a $340,000 conversion obligation.
- The reported conversions totaled $525,000 and 2,157,340 common shares.
- The filing does not provide the remaining principal balance of the note, the conversion price, or the company’s total shares outstanding after the issuances.
Financial Metrics, Liquidity, and Capital Structure
This filing does not report revenue, profit, cash flow, operating margins, cash balances, or broader liquidity metrics. The transactions reduced obligations under a senior secured convertible note through equity issuance rather than cash repayment, but the filing does not clearly quantify the resulting change in total debt or available liquidity.
Offering Exemption and Other Terms
The shares were issued to an existing securityholder without commissions, public offering activity, general solicitation, or general advertising. The company relied on the exemption under Section 3(a)(9), or alternatively Section 4(a)(2) and/or Rule 506 of Regulation D under the Securities Act, together with applicable state securities law exemptions.
Outlook, Risks, and Unusual Items
- The conversions may increase the number of shares outstanding and create dilution for existing shareholders.
- The note is senior secured and convertible; the filing does not disclose its current balance, maturity, interest terms, collateral, or additional conversion obligations.
- The filing provides no earnings guidance or operating outlook.
- The source text identifies September 22, 2026 as the report’s earliest event date, while describing a share issuance on September 23, 2026 and signing the report on September 25, 2026; investors should verify the applicable event and filing dates in the official filing.
Investor Verification Checklist
- Verify the post-issuance shares outstanding and the resulting ownership dilution.
- Review the full note and amended SPA for the remaining principal, conversion formula, interest, maturity, security interests, and default provisions.
- Confirm whether further conversions, share issuances, or registration obligations remain outstanding.
- Assess the company’s latest cash position, financing needs, and ability to meet senior secured debt obligations.
- Confirm the securities-law exemption and transfer or resale restrictions applicable to the issued shares.